# A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

> **NCT02857998** · PHASE1 · COMPLETED · sponsor: **Hutchison Medipharma Limited** · enrollment: 134 (actual)

## Conditions studied

- Mature B-cell Neoplasms

## Interventions

- **DRUG:** HMPL-523

## Key facts

- **NCT ID:** NCT02857998
- **Lead sponsor:** Hutchison Medipharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-27
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02857998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02857998, "A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02857998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*